39232-06-9Relevant academic research and scientific papers
Site-Selective, Remote sp3 C?H Carboxylation Enabled by the Merger of Photoredox and Nickel Catalysis
Sahoo, Basudev,Bellotti, Peter,Juliá-Hernández, Francisco,Meng, Qing-Yuan,Crespi, Stefano,K?nig, Burkhard,Martin, Ruben
supporting information, p. 9001 - 9005 (2019/06/24)
A photoinduced carboxylation of alkyl halides with CO2 at remote sp3 C?H sites enabled by the merger of photoredox and Ni catalysis is described. This protocol features a predictable reactivity and site selectivity that can be modulated by the ligand backbone. Preliminary studies reinforce a rationale based on a dynamic displacement of the catalyst throughout the alkyl side chain.
Synthesis and docking of novel piperidine renin inhibitors
Harmsen, Rianne A. G.,Sivertsen, Annfrid,Michetti, Davide,Brandsdal, Bjorn Olav,Sydnes, Leiv K.,Haug, Bengt Erik
, p. 479 - 494 (2013/07/26)
A series of 4-triazolyl-substituted piperidine derivatives were synthesized from N-Boc protected trans-4-ethynyl-3-hydroxypiperidine and tested as novel renin inhibitors. Piperidine derivatives containing a 1-substituted 1,2,3-triazol-5-yl substituent were found to be most active. Molecular docking experiments provide a rank order that is in agreement with experimental data. Furthermore, all compounds explore the S1 and the S3 subpockets through the piperidine substituents.
Use of triazolylpiperidine derivatives
-
Paragraph 0062, (2013/07/25)
The present invention relates to triazolylpiperidine compounds useful for the treatment of hypertension and diseases, disorders or conditions due to or involving hypertension and high blood pressure. In particular, the present invention relates to substituted triazolylpiperidine compounds representing inhibitors of aspartic proteases, in particular, of renin. Further, the present invention relates to pharmaceutical compositions containing the same useful in the treatment or prophylaxis of hypertension, preferably of essential hypertension
COMPOUND WITH SEROTONINERGIC ACTIVITY, PROCESS FOR PREPARING IT AND PHARMACEUTICAL COMPOSITION COMPRISING IT
-
Page/Page column 35-36, (2010/04/03)
Compound of formula (I) in which R1, R2 and R3 are defined in the following description, and the pharmaceutically acceptable acid-addition or base-addition salts thereof. The invention also relates to a process and an intermediate for preparing it, and to a pharmaceutical composition comprising it. The invention also relates to the use of a novel 2H-pyrrolo[3,4-c]quinoline compound for preparing a pharmaceutical composition that is active in the treatment of disturbances of the serotoninergic system.
Synthesis and evaluation of functionalized isoindigos as antiproliferative agents
Wee, Xi Kai,Yeo, Wee Kiang,Zhang, Bing,Tan, Vincent B. C.,Lim, Kian Meng,Tay, Tong Earn,Go, Mei-Lin
experimental part, p. 7562 - 7571 (2011/03/17)
A series of functionalized isoindigos structurally related to meisoindigo (1-methylisoindigo), a therapeutic agent used for the treatment of a form of leukemia, were synthesized and evaluated for antiproliferative activities on a panel of human cancer cells. Two promising compounds (1 -phenpropylisoindigo and 1-(p-methoxy-phenethyl)-isoindigo) that were more potent than meisoindigo and comparable to 6bromoindirubin-3'-oxime on leukemic K562 and liver HuH7 cells were identified. Structure-activity relationships showed the importance of keeping one of the lactam NH in an unsubstituted state. Substitution of the other lactam NH with aryl or arylalkyl side chains retained or improved activity in most instances. An intact exocyclic double bond was also essential, possibly to maintain planarity and rigidity of the isoindigo scaffold. None of the compounds were found to inhibit CDK2 in an in vitro assay, in spite of reports linking the antiproliferative activities of meisoindigo and other isoindigos to CDK2 inhibition. Hence, these functionalized isoindigos disrupted cell growth and proliferation by other mechanistic pathways that did not involve CDK2 inhibition.
Piperazine, piperidine and tetrahydropyridine derivative of indol-3-alkyl as 5-HT1D-α agonists
-
, (2008/06/13)
Compounds of formula (I), or a salt or prodrug thereof, wherein Z represents an optionally substituted five-membered heteroaromatic ring selected from furan, thiophene, pyrrole, oxazole, thiazole, isoxazole, isothiazole, imidazole, pyrazole, oxadiazole, thiadiazole, triazole and tetrazole; E represents a chemical bond or a straight or branched alkylene chain containing from 1 to 4 carbon atoms; Q represents a straight or branched alkylene chain containing from 1 to 6 carbon atoms, optionally substituted in any position by a hydroxy group; T represents nitrogen or CH; U represents nitrogen or C--R2 ; V represents oxygen, sulphur or N--R3 ; --F--G-- represents --CH2--N--, --CH2--CH-- or --CH=C--; R1 represents C3-6 alkenyl, C3-6 alkynyl, aryl(C1-6)alkyl or heteroaryl(C1-6)alkyl, any of which groups may be optionally substituted; and R2 and R3 independently represent hydrogen or C1-6 alkyl are selective agonists of 5-HT1D receptors, being potent agonists of the human 5-HT1Dalpha receptor subtype, while possessing at least a 10-fold selective affinity for the 5-HT1Dalpha receptor subtype, relative to the 5-HT1Dbeta subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT1D receptors is indicated, while eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT1D receptor agonists.
